Get to Know These 3 IPOs...

It’s the first week of February and there’s already a great lineup for the IPO market this week. Here are the details on three IPOs that are expected to go public in the second half of the week. It’s the first week of February and there’s already a great lineup for the IPO market this week. Here are the details on three IPOs that are expected to go public in the second half of the week. [Wealth Daily logo] Get to Know These 3 IPOs... [Monica Savaglia Photo] By [Monica Savaglia]( Written Feb 02, 2021 It’s been an interesting week, to say the least. Investing and market trends have been spotlighted a great deal in the past week because of recent news involving GameStop (NYSE: GME). A company that was on the verge of going bankrupt is now on everyone’s radar. Whether you’re an investor or not, it’s been hard not to hear about GameStop and the investing drama surrounding it. As I write this, GameStop stock has opened the day at $316.25 per share. I don’t want to get into too much detail since a colleague of mine, Jason Williams, wrote an [excellent article]( about the drama surrounding [GameStop and the Reddit board (r/wallstreetbets)]( behind this recent uptick. I just thought it would be worth noting to direct you to an article that focuses more on it. Today, I want to talk about my favorite topic to discuss with all of you — the IPO market. Last week, I spoke briefly about how we are still experiencing a [SPAC surge]( — that’s still the case this week. Though there are a few SPACs set to IPO this week, it appears IPOs from non-blank check companies will dominate. I want to focus on three public offerings that might interest you. Keep an eye out for these market debuts. BUY ALERT: Announcing My New Recommendation I’ve just found my newest 10-Day Jackpot stock. I’ll be releasing it tomorrow, so this is your last chance to be among the first to hear about it. Like all my 10-Day Jackpot trades, I think this one has the potential to deliver a year's worth of gains in as little as 10–15 days. But you must RSVP by midnight. [Click here to see how you can get tomorrow’s trade before it’s too late.]( 1. ON24 ON24 is based in San Francisco, California, and offers online video communications and related sales and marketing support technologies to businesses throughout the world. As you know, a lot of work and interaction has shifted to mostly virtual because of the COVID-19 pandemic. ON24 provides a cloud-based digital experience platform to its business clients, offering online webinar software, virtual events, multimedia content, behavioral insights, and a third-party app ecosystem. So much is virtual right now and that has increased the demand for offerings like those of ON24. According to the company, as of September 30, 2020, it had more than 1,900 customers in over 40 countries. The high demand for these types of services during the pandemic could continue in a post-pandemic world. Even as far back as 2018, this market was forecasted to grow. A 2018 market research report by Global Market Insights indicated that the global market for video conferencing is expected to exceed $20 billion by 2024, which represents a forecast CAGR of 10%. Many businesses have stated that they will be sticking with remote work even after the pandemic — a sign that demand for video conferencing and the types of services that ON24 offers will continue. The company is set to go public this Wednesday, February 3 on the NYSE under the ticker symbol “ONTF.” Its underwriters include Goldman Sachs, JPMorgan, and KeyBanc Capital Markets. As of right now, its target price range is $45–$50 per share. Zoom Video Communications (NASDAQ: ZM) provides video conferencing for businesses and personal use, so this IPO from ON24 could be comparable. 2. loanDepot LoanDepot is based in Foothill Ranch, California, and has developed a digital-first platform that allows for origination, processing, underwriting, closing, and servicing for residential mortgages in the U.S. Its main mission is to provide these otherwise complicated and time-consuming services in a more efficient manner. Right now, interest rates are at record lows, and loanDepot has joined the wave of other mortgage leaders who aim to benefit from these rates. The company is one of America’s largest mortgage lenders. In loanDepot’s S-1, it reported that its market share is growing from just over 1% in 2014 to 2.6% as of September 30, 2020. The company earned $3.4 billion in revenue in the 12 months that ended on September 30, 2020. While we are seeing an upward trend in this market because of the COVID-19 pandemic and lower interest rates, that demand could fizzle when the economy starts to rebound and interest rates start to increase. Back in September, Bloomberg reported that loanDepot was eyeing an IPO that would see the company valued between $12 billion and $15 billion. The company is set to go public this Thursday, February 4 on the NYSE under the ticker symbol “LDI.” Its underwriters include Goldman Sachs, Bank of America Securities, Credit Suisse, Morgan Stanley, Barclays, Citigroup, Jefferies, and UBS Investment Bank. As of right now, it has a target price range of $19–$21 per share. There is growing investor interest in this IPO, so I believe that its shares will most likely be on the high end or even above that target price range. The Only Way to Survive in This Market Ex-Wall Street banker Jason Williams here. And you’re right about these markets: A LOT of money will be lost. But here’s the thing — that money is NOT going to disappear. Instead, it’s going to be snapped up by financial insiders who know how to weather the storm. [Find out what they’re doing](, and how you can do the same, when you claim an emergency FREE copy of my brand-new book [Endless Income: 67 Hidden Wealth Hacks Used by the Ultra Rich.]( 3. Lucira Health Just like the other two IPOs mentioned in this article, Lucira Health is also based in California. It has developed a line of convenient testing kits, and its lead kit is being developed for the detection of the COVID-19 virus. The company recently received emergency marketing approval from the FDA for its COVID-19 test device. This is a prescription at-home self-collected nasal swab for individuals aged 14 and older who are suspected of having COVID-19. The kit will be able to test for the presence of the COVID-19 virus within 30 minutes of sample collection. Right now, Lucira is ramping up its manufacturing capacity for its COVID-19 test kit, and it believes that it can scale its operations significantly in the second half of 2021. Obviously, the COVID-19 virus has provided many challenges to the U.S. health care system, and the availability of a kit like Lucira’s could be extremely beneficial to lighten the load that health care systems are faced with every day — especially since it can be performed at home and only takes 30 minutes to produce results. The company is set to go public this Friday, February 5 on the Nasdaq under the ticker symbol “LHDX.” Its underwriters include Bank of America Securities, William Blair, and LifeSci Capital. As of right now, it has a target price range of $15–$17 per share. Keep an eye out for these IPOs and how they perform on their market debuts. For more information and news on upcoming IPOs, [click here.]( Until next time, [Monica Savaglia Signature Park Avenue Digest] Monica Savaglia --------------------------------------------------------------- This Tech Fights Back Against COVID Variants There are so many COVID mutations out right now that I’m starting to lose count. The UK variant… the South African variant… and now there's one from Brazil. Just remember: We’re fighting a virus… and viruses will mutate. As Americans get vaccinated at warp speed, scientists say that these new vaccines will also help fight the new strains. But who really knows? We’re in uncharted territory. There seems like no end in sight. When can we get back to our “normal” pre-COVID lives? Honestly, we can’t have kids in virtual learning forever, and we can’t stay in forever. It’s just not healthy, both mentally and physically. That’s why I’m looking to invest in this company that has developed the technology to detect a fever and other symptoms even before the infected enters a building or any other establishment. This company’s tech will mitigate infections for years to come. And it doesn’t stop at the door. This technology also monitors everyone inside, including those who are not following social distancing protocols. There’s a lot more this technology can do. [Click here for the full story of why now is the time to get in on this company…]( Browse Our Archives [The Curious Case of the GameStop Short Squeeze]( [GameStop ($GME) Proved the Market Is RIGGED]( [When Shorting Stocks goes All Wrong]( [What's Going on With All These SPACs?]( [The Return of the Story Stocks]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletter@wealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Wealth Daily](, Copyright © 2021, [Angel Publishing LLC](. All rights reserved. 3 E Read Street Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Wealth Daily]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.